Table 1.
Anti-proliferative profiles of TB, AJ, paclitaxel (PTX), and AJ-HP-β-CD in various human cancer cell lines.
| Cell Line | Origin | IC50 (nM) | |||
|---|---|---|---|---|---|
| Taccalonolide B | Taccalonolide AJ | PTX | AJ-HP-β-CD | ||
| A2780 | Epithelial ovarian cancer | >30,000 | 6.18 ± 0.446 | 1.87 ± 0.37 | 2.06 ± 0.13 |
| 786-O | Primary clear renal cell carcinoma | 26,100.27 | 16.01 ± 1.54 | 4.85 ± 0.46 | 3.51 ± 0.79 |
| ACHN | Metastatic papillary renal cell carcinoma | >30,000 | 35.96 ± 1.08 | 5.57 ± 0.28 | 9.82 ± 1.02 |
| HepG2 | Hepatocellular carcinoma | >30,000 | 9.49 ± 0.64 | 2.94 ± 0.25 | 1.90 ± 0.23 |
| Hep-3B | Hepatocellular carcinoma | >30,000 | 8.36 ± 0.28 | 4.50 ± 0.57 | 1.90 ± 0.06 |
| Huh-7 | Hepatocellular carcinoma | >30,000 | 9.96 ± 0.21 | 5.18 ± 0.03 | 3.09 ± 0.20 |
| HCT116 | Human colorectal carcinoma | >30,000 | 14.62 ± 1.13 | 3.83 ± 0.35 | 4.24 ± 0.51 |
| MCF-7 | Human breast carcinoma | >30,000 | 23.87 ± 1.71 | 3.41 ± 0.69 | 16.54 ± 0.49 |